Document Detail


Aflibercept.
MedLine Citation:
PMID:  22460118     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.
Authors:
Michael W Stewart; Seden Grippon; Peter Kirkpatrick
Related Documents :
8660398 - Antioxidants in food packaging: a risk factor?
10620268 - Production of tomato flavor volatiles from a crude enzyme preparation using a hollow-fi...
12747218 - Antioxidant actions of polyphenols in humans.
12564688 - On-line solid-phase extraction of ceramides from yeast with ceramide iii imprinted mono...
6735998 - Patient compliance with mao inhibitor therapy.
24812518 - Nutritional status of water-soluble vitamins did not differ according to intake levels ...
Publication Detail:
Type:  News     Date:  2012-03-30
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-30     Completed Date:  2012-06-05     Revised Date:  2013-02-28    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  269-70     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials, Phase III as Topic
Double-Blind Method
Humans
Randomized Controlled Trials as Topic
Recombinant Fusion Proteins / adverse effects,  therapeutic use*
United States
United States Food and Drug Administration
Wet Macular Degeneration / drug therapy*
Chemical
Reg. No./Substance:
0/Recombinant Fusion Proteins; 15C2VL427D/aflibercept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Defining rewardable innovation in drug therapy.
Next Document:  Novel molecular targets for atrial fibrillation therapy.